Dr. Yael Mosse

Biography

Yael P. Mosse, M.D., is a Professor in the Department of Pediatrics at the University of Pennsylvania's Perelman School of Medicine and a physician-scientist focused on neuroblastoma. She is known for her seminal discovery of activating mutations in the ALK oncogene, which is a major cause of hereditary neuroblastoma, and for identifying somatically acquired ALK mutations that drive malignant processes in sporadic tumors. Dr. Mosse has successfully led efforts to translate her research into clinical applications, culminating in the initiation of phase 1 and ongoing phase 2 trials using the ALK inhibitor crizotinib. Her work has established ALK as a tractable molecular target and fostered collaborative studies showing the potential of targeted therapy in treating neuroblastoma. As co-leader of the world's largest developmental therapeutics program for children with refractory neuroblastoma, she works towards improving cure rates through innovative therapeutic strategies that integrate expertise in translational genomics and pharmacology. Dr. Mosse's commitment to bridging the gap between laboratory discoveries and clinical applications is reflected in her rapid translation of research findings into effective treatment pathways for patients with diverse and complex neuroblastoma tumors.

Research Interests